AU2003286802A1 - Methods for the treatment, prevention and management of macular degeneration - Google Patents

Methods for the treatment, prevention and management of macular degeneration Download PDF

Info

Publication number
AU2003286802A1
AU2003286802A1 AU2003286802A AU2003286802A AU2003286802A1 AU 2003286802 A1 AU2003286802 A1 AU 2003286802A1 AU 2003286802 A AU2003286802 A AU 2003286802A AU 2003286802 A AU2003286802 A AU 2003286802A AU 2003286802 A1 AU2003286802 A1 AU 2003286802A1
Authority
AU
Australia
Prior art keywords
heterocycle
alkyl
aryl
arylalkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286802A
Other languages
English (en)
Inventor
Jerome B. Zeldis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2003286802A1 publication Critical patent/AU2003286802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003286802A 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration Abandoned AU2003286802A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42289602P 2002-10-31 2002-10-31
US60/422,896 2002-10-31
US10/699,105 US20040092568A1 (en) 2002-10-31 2003-10-30 Methods for the treatment, prevention and management of macular degeneration
US10/699,105 2003-10-30
PCT/US2003/034662 WO2004041191A2 (en) 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration

Publications (1)

Publication Number Publication Date
AU2003286802A1 true AU2003286802A1 (en) 2004-06-07

Family

ID=32233518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286802A Abandoned AU2003286802A1 (en) 2002-10-31 2003-10-31 Methods for the treatment, prevention and management of macular degeneration

Country Status (11)

Country Link
US (1) US20040092568A1 (enExample)
EP (1) EP1565188A2 (enExample)
JP (1) JP2006507307A (enExample)
KR (1) KR20050061596A (enExample)
AU (1) AU2003286802A1 (enExample)
BR (1) BR0315939A (enExample)
CA (1) CA2504028A1 (enExample)
MX (1) MXPA05004550A (enExample)
NZ (1) NZ540187A (enExample)
TW (1) TW200420290A (enExample)
WO (1) WO2004041191A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
ES2284308B1 (es) * 2005-03-08 2008-08-01 Bsh Electrodomesticos España, S.A. Tambor para maquina lavadora de ropa.
CA2663545A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
EP2374825A1 (en) 2008-12-17 2011-10-12 Keio University Photodynamic therapeutic agent showing accumulation of cell-specific functions
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
ES2463826T3 (es) 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
CN115784993A (zh) * 2022-11-23 2023-03-14 四川大学华西医院 一种3-氨基吲唑类化合物的制备及其治疗帕金森病的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto

Also Published As

Publication number Publication date
NZ540187A (en) 2008-03-28
BR0315939A (pt) 2005-09-13
MXPA05004550A (es) 2005-07-26
WO2004041191A3 (en) 2004-12-02
EP1565188A2 (en) 2005-08-24
CA2504028A1 (en) 2004-05-21
JP2006507307A (ja) 2006-03-02
KR20050061596A (ko) 2005-06-22
TW200420290A (en) 2004-10-16
WO2004041191A2 (en) 2004-05-21
US20040092568A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
RU2297243C2 (ru) Ингибиторы киназы-3 гликогенсинтазы (gsk-3) для лечения глаукомы
AU2003284980B2 (en) Treatment of pain with JNK inhibitors
US20040092568A1 (en) Methods for the treatment, prevention and management of macular degeneration
US20060122179A1 (en) Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury
AU2003300466A1 (en) Drug-coated stents and methods of use therefor
AU2002334635A1 (en) Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
AU2006325706A1 (en) Control of intraocular pressure using ALK5 modulation agents
IL126836A (en) Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
AU2003256259A1 (en) Methods for using jnk inhibitors for treating or preventing disease-related wasting
AU2006287765B2 (en) P13K inhibitors for the treatment of endometriosis
CN1732003A (zh) 用于治疗、预防和控制黄斑变性的方法
CN101300047A (zh) Pi3k抑制剂用于子宫内膜异位症的治疗
HK1088221A (en) Methods for the treatment, prevention and management of macular degeneration
TW201335149A (zh) 治療視網膜疾病之方法
HK1123234A (en) Pi3k inhibitors for the treatment of endometriosis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application